Business
NexgenRx Announces 2025 Year End Results with Continued Increasing Net Income, EBITDA And Revenue Growth
TORONTO, ON / ACCESS Newswire / March 31, 2026 / NEXGENRX INC. ("NexgenRx" or the "Company")...
About this update from Nexgenrx Inc.
[{"type":"text","content":"NexgenRx Announces 2025 Year End Results with Continued Increasing Net Income, EBITDA And Revenue GrowthTORONTO, ON / ACCESS Newswire / March 31, 2026 / NEXGENRX INC. (\"NexgenRx\" or the \"Company\") is pleased to announce its annual financial results for the financial year ended December 31, 2025, with net income and EBITDA improving to $3,350,704 (an increase of $1,011,282 as compared to 2024), net income increasing to $1,289,735 (an increase of $675,166 as compared to 2024) and revenues increasing by $1,457,136, to $14,933,914.The 2025 financial year marked a period of disciplined execution and continued investment in the Company's long-term growth. Throughout the year, the Company remained focused on strengthening its foundation by advancing development initiatives, deepening relationships with its existing clients, and enhancing the value that it delivers. These efforts resulted in organic growth of 12% in administration and transaction revenue combined, reflecting both the resilience of the Company's business model and the trust of its customers.Financially, the Company delivered solid performance in 2025. Total revenue increased by $1,457,136 (to $14,933,914), representing growth of 8.84% over the prior year. The Company achieved a positive EBITDA of $3,350,704, with net income and EBITDA improving by $675,166 and $1,011,282, respectively, compared to 2024. The Company's cash position remained robust at $4,776,670, even after distributing $1,297,757 in dividends to common and preferred shareholders during the year.Looking ahead to 2026, management will maintain a strong emphasis on converting the Company's sales pipeline through a range of strategic initiatives. The Company is committed to expanding its market presence and driving further growth by introducing new and innovative product solutions that meet the evolving needs of the Company's clients.Ron Loucks, President and CEO, stated \"2025 was another excellent year for NexgenRx. With a strong base of recurring revenue and a healthy sales pipeline, the Company is well positioned to continue generating sustainable free cash flow. We remain confident in our strategy and our ability to deliver long-term value to our shareholders. I would like to extend my continued sincere appreciation to our loyal shareholders and our Board of Directors for their continued guidance, su...